Close

Inovio Pharmaceuticals (INO) Unlikely to be a COVID Vaccine Contender, Roth Capital Reiterates Sell

August 11, 2020 6:21 AM EDT Send to a Friend
Roth Capital analyst Jonathan Aschoff reiterated a Sell rating and $11.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login